Orient Europharma Co (ROCO:4120) Other Current Receivables: NT$249 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
61 GF Score
Price NT$45.70
GF Value NT$47.36
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Orient Europharma Co Other Current Receivables?

Orient Europharma Co ROCO:4120 -3.38% 61 Other Current Receivables is NT$249 Mil as of Jun. 2026. GuruFocus rates ROCO:4120 with a GF Score™ of 61/100 and a GF Value™ of NT$47.36 (Fairly Valued). The stock has 5 warning signs investors should review.

Orient Europharma Co's Other Current Receivables for the quarter that ended in Jun. 2026 was NT$249 Mil.

Orient Europharma Co's quarterly Other Current Receivables increased from Dec. 2025 (NT$76.97 Mil) to Mar. 2026 (NT$124.01 Mil) and increased from Mar. 2026 (NT$124.01 Mil) to Jun. 2026 (NT$249.49 Mil).

Orient Europharma Co's annual Other Current Receivables declined from Dec. 2023 (NT$143.04 Mil) to Dec. 2024 (NT$93.56 Mil) and declined from Dec. 2024 (NT$93.56 Mil) to Dec. 2025 (NT$76.97 Mil).

Orient Europharma Co Other Current Receivables Related Terms

Orient Europharma Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Orient Europharma Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co Other Current Receivables Chart

Orient Europharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.34 103.91 143.04 93.56 76.97

Orient Europharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.00 91.91 76.97 124.01 249.49
ROCO:4120
61GF Score
Orient Europharma Co Ltd ROCO:4120
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Europharma Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$249 Mil mean?
Orient Europharma Co (ROCO:4120) has a Other Current Receivables of NT$249 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Orient Europharma Co and its competitors.
Is Orient Europharma Co's Other Current Receivables too high?
Orient Europharma Co's current Other Current Receivables is NT$249 Mil. Overall, Orient Europharma Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Other Current Receivables compare to ZTS?
Orient Europharma Co's Other Current Receivables of NT$249 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Orient Europharma Co and its competitors. Orient Europharma Co's current Other Current Receivables is NT$249 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$47.36, compared to a current price of NT$45.70 — trading 3.5% below its estimated fair value. The current Other Current Receivables is NT$249 Mil. Orient Europharma Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Other Current Receivables is NT$249 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$45.70 is trading 3.5% below its estimated GF Value™ of NT$47.36. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • Other Current Receivables: NT$249 Mil
  • GF Value™: NT$47.36 vs. price of NT$45.70 (3.5% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
61GF Score

Get the complete analysis for ROCO:4120

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$45.70
Price
NT$47.36
GF Value